ozanimod is a novel selective oral sphingosine 1 phosphate 1 and 5 receptor modulator in development for multiple sclerosis and inflammatory bowel disease this randomized double blind placebo controlled positive controlled parallel group thorough qt study characterized the effects of ozanimod on cardiac repolarization in healthy subjects eligible subjects were randomized to 1 of 2 groups ozanimod escalated from 0 25 to 2 mg over 14 days or placebo for 14 days a single dose of moxifloxacin 400 mg or placebo was administered on days 2 and 17 the primary end point was the time matched placebo corrected baseline adjusted mean qtcf δδqtcf a total of 113 124 91 1 subjects completed the study the upper limits of the 2 sided 90 confidence intervals for δδqtcf for both ozanimod 1 and 2 mg were below the 10 millisecond regulatory threshold no qtcf 480 milliseconds or postdose change in qtcf of 60 milliseconds was observed there was no evidence of a positive relationship between concentrations of ozanimod and its active metabolites and δδqtcf although ozanimod blunted the observed diurnal increase in heart rate excursions below predose heart rates were no greater than with placebo results demonstrate that ozanimod does not prolong the qtc interval or cause clinically significant bradycardia supporting ozanimod s evolving favorable cardiac safety profile.